Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 17 |
| List of Tables | 16 | 2 |
| List of Figures | 18 | 1 |
| Introduction | 19 | 1 |
| Global Markets Direct Report Coverage | 19 | 1 |
| Cervical Cancer Overview | 20 | 1 |
| Therapeutics Development | 21 | 2 |
| Pipeline Products for Cervical Cancer Overview | 21 | 1 |
| Pipeline Products for Cervical Cancer Comparative Analysis | 22 | 1 |
| Cervical Cancer Therapeutics under Development by Companies | 23 | 6 |
| Cervical Cancer Therapeutics under Investigation by Universities/Institutes | 29 | 1 |
| Cervical Cancer Pipeline Products Glance | 30 | 4 |
| Late Stage Products | 30 | 1 |
| Clinical Stage Products | 31 | 1 |
| Early Stage Products | 32 | 1 |
| Unknown Stage Products | 33 | 1 |
| Cervical Cancer Products under Development by Companies | 34 | 7 |
| Cervical Cancer Products under Investigation by Universities/Institutes | 41 | 1 |
| Cervical Cancer Companies Involved in Therapeutics Development | 42 | 75 |
| Abion Inc | 42 | 1 |
| Admedus Ltd | 43 | 1 |
| Advaxis Inc | 44 | 1 |
| Advenchen Laboratories LLC | 45 | 1 |
| Antigen Express Inc | 46 | 1 |
| Arbor Vita Corp | 47 | 1 |
| ArQule Inc | 48 | 1 |
| AstraZeneca Plc | 49 | 1 |
| AVEO Pharmaceuticals Inc | 50 | 1 |
| Azaya Therapeutics Inc | 51 | 1 |
| Bioleaders Corporation | 52 | 1 |
| Biomics Biotechnologies Co Ltd | 53 | 1 |
| Blirt SA | 54 | 1 |
| Boehringer Ingelheim GmbH | 55 | 1 |
| Bristol-Myers Squibb Company | 56 | 1 |
| Cancer Research Technology Ltd | 57 | 1 |
| Cell Medica Ltd | 58 | 1 |
| Cellceutix Corp | 59 | 1 |
| Coherus BioSciences Inc | 60 | 1 |
| Critical Outcome Technologies Inc | 61 | 1 |
| CZ BioMed Corp | 62 | 1 |
| DelMar Pharmaceuticals, Inc. | 63 | 1 |
| Dr. Reddy's Laboratories Ltd | 64 | 1 |
| EirGenix Inc. | 65 | 1 |
| Eisai Co Ltd | 66 | 1 |
| Etubics Corp | 67 | 1 |
| Eureka Therapeutics Inc | 68 | 1 |
| EyeGene Inc | 69 | 1 |
| F. Hoffmann-La Roche Ltd | 70 | 1 |
| Formune SL | 71 | 1 |
| GamaMabs Pharma SA | 72 | 1 |
| Gene Techno Science Co Ltd | 73 | 1 |
| Genexine Inc | 74 | 1 |
| Genmab A/S | 75 | 1 |
| Genor BioPharma Co Ltd | 76 | 1 |
| Genticel S.A. | 77 | 1 |
| GlaxoSmithKline Plc | 78 | 1 |
| Immune Therapeutics, Inc. | 79 | 1 |
| Immunovaccine Inc | 80 | 1 |
| INSYS Therapeutics Inc | 81 | 1 |
| ISA Pharmaceuticals BV | 82 | 1 |
| Johnson &Johnson | 83 | 1 |
| Karyopharm Therapeutics Inc | 84 | 1 |
| Kite Pharma Inc | 85 | 1 |
| LondonPharma Ltd | 86 | 1 |
| Mabion SA | 87 | 1 |
| Merck &Co Inc | 88 | 1 |
| Mycenax Biotech Inc | 89 | 1 |
| Nanotherapeutics Inc | 90 | 1 |
| Nektar Therapeutics | 91 | 1 |
| Oncobiologics Inc | 92 | 1 |
| Ono Pharmaceutical Co Ltd | 93 | 1 |
| Oryx GmbH &Co KG | 94 | 1 |
| PDS Biotechnology Corp | 95 | 1 |
| Pfizer Inc | 96 | 1 |
| Psicofarma SA de CV | 97 | 1 |
| Rexahn Pharmaceuticals Inc | 98 | 1 |
| Richter Gedeon Nyrt | 99 | 1 |
| Samyang Holdings Corp | 100 | 1 |
| Sanofi | 101 | 1 |
| Savoy Pharmaceuticals, Inc. | 102 | 1 |
| Seattle Genetics Inc | 103 | 1 |
| Selecta Biosciences Inc | 104 | 1 |
| Shantha Biotechnics Ltd | 105 | 1 |
| Sirnaomics Inc | 106 | 1 |
| Sun Pharma Advanced Research Company Ltd | 107 | 1 |
| Taiho Pharmaceutical Co Ltd | 108 | 1 |
| Tessa Therapeutics Pte Ltd | 109 | 1 |
| Theravectys SA | 110 | 1 |
| THEVAX Genetics Vaccine USA Inc | 111 | 1 |
| Tomegavax Inc | 112 | 1 |
| UbiVac LLC | 113 | 1 |
| VLPbio | 114 | 1 |
| Zeria Pharmaceutical Co Ltd | 115 | 1 |
| Zydus Cadila Healthcare Ltd | 116 | 1 |
| Cervical Cancer Therapeutics Assessment | 117 | 16 |
| Assessment by Monotherapy Products | 117 | 1 |
| Assessment by Combination Products | 118 | 1 |
| Assessment by Target | 119 | 5 |
| Assessment by Mechanism of Action | 124 | 5 |
| Assessment by Route of Administration | 129 | 2 |
| Assessment by Molecule Type | 131 | 2 |
| Drug Profiles | 133 | 318 |
| (hydralazine + valproate magnesium) Drug Profile | 133 | 1 |
| ABN-301 Drug Profile | 134 | 1 |
| AEH-10p Drug Profile | 135 | 1 |
| AL-3818 Drug Profile | 136 | 2 |
| Ancer Drug Profile | 138 | 1 |
| Antisense RNAi Oligonucleotide for Cervical Cancer Drug Profile | 139 | 1 |
| Aptamer to Target HPV E7 Protein for Cervical Cancer Drug Profile | 140 | 1 |
| ARQ-092 Drug Profile | 141 | 3 |
| artemether Drug Profile | 144 | 2 |
| atezolizumab Drug Profile | 146 | 14 |
| AV-203 Drug Profile | 160 | 3 |
| AVC-7 Drug Profile | 163 | 1 |
| axalimogene filolisbac Drug Profile | 164 | 17 |
| AZD-5363 Drug Profile | 181 | 3 |
| bevacizumab biosimilar Drug Profile | 184 | 2 |
| bevacizumab biosimilar Drug Profile | 186 | 1 |
| bevacizumab biosimilar Drug Profile | 187 | 1 |
| bevacizumab biosimilar Drug Profile | 188 | 1 |
| bevacizumab biosimilar Drug Profile | 189 | 1 |
| bevacizumab biosimilar Drug Profile | 190 | 1 |
| bevacizumab biosimilar Drug Profile | 191 | 1 |
| bevacizumab biosimilar Drug Profile | 192 | 1 |
| bevacizumab biosimilar Drug Profile | 193 | 1 |
| bevacizumab biosimilar Drug Profile | 194 | 1 |
| bevacizumab biosimilar Drug Profile | 195 | 1 |
| BLR-111 Drug Profile | 196 | 1 |
| BLSILSB-710c Drug Profile | 197 | 1 |
| BMS-986016 Drug Profile | 198 | 2 |
| BVAC-C Drug Profile | 200 | 1 |
| Cellular Immunotherapy for HPV Associated Cancers Drug Profile | 201 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 202 | 1 |
| Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer Drug Profile | 203 | 2 |
| Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer Drug Profile | 205 | 2 |
| CerviVax Drug Profile | 207 | 1 |
| Cervlysis Drug Profile | 208 | 1 |
| CIGB-300 Drug Profile | 209 | 2 |
| CMD-004 Drug Profile | 211 | 1 |
| COTI-2 Drug Profile | 212 | 8 |
| crocetin Drug Profile | 220 | 1 |
| dianhydrogalactitol Drug Profile | 221 | 12 |
| docetaxel Drug Profile | 233 | 2 |
| DPXE-7 Drug Profile | 235 | 1 |
| E-7046 Drug Profile | 236 | 1 |
| EDA-HPVE7 Drug Profile | 237 | 1 |
| EDOB-278 Drug Profile | 238 | 1 |
| EF-022 Drug Profile | 239 | 1 |
| EG-HPV Drug Profile | 240 | 1 |
| Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer Drug Profile | 241 | 1 |
| ET-1502 Drug Profile | 242 | 1 |
| ETBX-041 Drug Profile | 243 | 1 |
| etirinotecan pegol Drug Profile | 244 | 6 |
| GM-102 Drug Profile | 250 | 2 |
| GSK-2256098 Drug Profile | 252 | 2 |
| GSK-2849330 Drug Profile | 254 | 1 |
| GTL-001 Drug Profile | 255 | 3 |
| GTL-002 Drug Profile | 258 | 1 |
| GX-I7 Drug Profile | 259 | 1 |
| HPViNT Drug Profile | 260 | 1 |
| human papillomavirus vaccine Drug Profile | 261 | 1 |
| human papillomavirus vaccine Drug Profile | 262 | 1 |
| human papillomavirus vaccine Drug Profile | 263 | 1 |
| human papillomavirus vaccine Drug Profile | 264 | 1 |
| human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar Drug Profile | 265 | 1 |
| ISA-101 Drug Profile | 266 | 3 |
| JNJ-61610588 Drug Profile | 269 | 1 |
| Kevetrin Drug Profile | 270 | 11 |
| KITE-439 Drug Profile | 281 | 1 |
| LN-145 Drug Profile | 282 | 2 |
| Lovaxin S Drug Profile | 284 | 1 |
| Monoclonal Antibody Conjugate to Target CD40 for Cervical, Head And Neck Cancer Drug Profile | 285 | 1 |
| naltrexone hydrochloride Drug Profile | 286 | 3 |
| nimotuzumab Drug Profile | 289 | 4 |
| nintedanib Drug Profile | 293 | 10 |
| NIT-02 Drug Profile | 303 | 1 |
| nivolumab Drug Profile | 304 | 34 |
| NP-001 Drug Profile | 338 | 1 |
| NTO-1151 Drug Profile | 339 | 2 |
| Oncoprev Drug Profile | 341 | 1 |
| OTAC-DCtag Drug Profile | 342 | 1 |
| paclitaxel Drug Profile | 343 | 2 |
| paclitaxel Drug Profile | 345 | 4 |
| paclitaxel albumin free Drug Profile | 349 | 1 |
| PDS-0101 Drug Profile | 350 | 2 |
| pembrolizumab Drug Profile | 352 | 38 |
| PF-04518600 Drug Profile | 390 | 2 |
| phosphoethanolamine Drug Profile | 392 | 1 |
| RA-190 Drug Profile | 393 | 1 |
| Recombinant Protein to Inhibit NFKB for Cervical Cancer and Breast Cancer Drug Profile | 394 | 1 |
| RG-7876 Drug Profile | 395 | 1 |
| RX-3117 Drug Profile | 396 | 5 |
| S-009131 Drug Profile | 401 | 1 |
| SAR-408701 Drug Profile | 402 | 1 |
| SEL-701 Drug Profile | 403 | 1 |
| selinexor Drug Profile | 404 | 19 |
| SGN-LIV1A Drug Profile | 423 | 2 |
| sirolimus albumin-bound Drug Profile | 425 | 2 |
| Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology Drug Profile | 427 | 1 |
| STP-900 Drug Profile | 428 | 1 |
| Subunit Vaccine for HPV Associated Cervical Cancer Drug Profile | 429 | 1 |
| Synthetic Peptides to Inhibit Bcl-x and MCL-1 for Oncology Drug Profile | 430 | 1 |
| TA-CIN Drug Profile | 431 | 1 |
| TAS-114 Drug Profile | 432 | 1 |
| Tenacinol Drug Profile | 433 | 1 |
| tisotumab vedotin Drug Profile | 434 | 2 |
| TT-12 Drug Profile | 436 | 1 |
| TVGV-1 Drug Profile | 437 | 1 |
| utomilumab Drug Profile | 438 | 2 |
| Vaccine for HPV Associated Cancers Drug Profile | 440 | 1 |
| Vaccine for HPV Associated Cervical Cancer Drug Profile | 441 | 1 |
| Vaccine for HPV Associated Cervical Cancer Drug Profile | 442 | 1 |
| Vaccine for HPV Associated Cervical Cancer Drug Profile | 443 | 1 |
| Vaccine for Human papillomavirus Associated Cervical Cancer Drug Profile | 444 | 1 |
| Vaccine to Target HIG2, VEGFR-1 and VEGFR-2 for Ovarian Cancer and Cervical Cancer Drug Profile | 445 | 1 |
| Vaccine to Target HPV E7 Protein for Cervical Cancer Drug Profile | 446 | 1 |
| Vaccine to Target HPV Minor Capsid Protein L2 for Cervical Cancer Drug Profile | 447 | 1 |
| Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer Drug Profile | 448 | 1 |
| Vicoryx Drug Profile | 449 | 1 |
| Vvax-001 Drug Profile | 450 | 1 |
| Cervical Cancer Dormant Projects | 451 | 7 |
| Cervical Cancer Discontinued Products | 458 | 1 |
| Cervical Cancer Product Development Milestones | 459 | 12 |
| Featured News &Press Releases | 459 | 1 |
| Nov 11, 2016: Advaxis to Present Phase 1 Combination Data and New Preclinical Data Using AXAL at Upcoming Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting | 459 | 1 |
| Oct 26, 2016: Immune Therapeutics Announces Filing Acceptance of New Drug Applications for Lodonal for the Treatment of Patients with Human Immuno-Deficiency, Cancer and as an Immune Booster | 460 | 1 |
| Oct 24, 2016: Advaxis Announces GOG-0265 12-month Overall Survival Rate of 37.5% in Stage 2 | 461 | 1 |
| Oct 20, 2016: Advaxis Initiates Phase 3 Study of Axalimogene Filolisbac | 462 | 1 |
| Oct 19, 2016: Kite Pharma provides update on KITE-439 clinical development program at Investor Day | 462 | 1 |
| Oct 05, 2016: Karyopharm to Present Updated SIGN Phase 2 Clinical Data at European Society of Medical Oncology 2016 Annual Meeting | 462 | 2 |
| Sep 26, 2016: Advaxis Lm Technology Immunotherapies to be Showcased in Three Poster Presentations at SITC Annual Meeting | 464 | 1 |
| Aug 23, 2016: Immune Therapeutics Through Its Wholly Owned Subsidiary TNI BioTech International Initiates Clinical Trial In Malawi With LDN For The Prevention Of Cervical Cancer | 464 | 1 |
| Jul 26, 2016: Phase 1/2 Combination Trial of AXAL and Durvalumab Completes Second Dose-Escalation Cohort | 465 | 1 |
| Jul 22, 2016: Genexine Confirms Possibility of Treatment in Cervicovaginal Tumor with Combination Therapy of hyFc-fused Interleukin-7 and HPV DNA Vaccine | 466 | 1 |
| Jul 21, 2016: Advaxis AXAL Receives Fast Track Designation by the FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients | 466 | 1 |
| Jul 18, 2016: European Medicines Agency Committee Classifies Advaxis Axalimogene Filolisbac as an Advanced-Therapy Medicinal Product | 467 | 1 |
| Jul 06, 2016: FDA Grants Special Protocol Assessment to Advaxis Phase 3 Study of AXAL in Patients with Cervical Cancer | 468 | 1 |
| Jun 06, 2016: Advaxis Announces Updated Data at ASCO from a Phase 2 Study of AXAL in Advanced Cervical Cancer Showing Promising Survival Rates Consistent with Earlier Reports | 468 | 1 |
| Jun 06, 2016: Critical Outcome Activates Second Clinical Trial Site for Its COTI-2 Gynecological Cancer Study | 469 | 2 |
| Appendix | 471 | 2 |
| Methodology | 471 | 1 |
| Coverage | 471 | 1 |
| Secondary Research | 471 | 1 |
| Primary Research | 471 | 1 |
| Expert Panel Validation | 471 | 1 |
| Contact Us | 471 | 1 |
| Disclaimer | 472 | 1 |